Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on ...

Merck unveiled encouraging Phase 3 KEYNOTE-689 trial results for KEYTRUDA at the AACR 2025 Meeting, sparking investor ...

The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...

The transaction is expected to close in the second half of 2025. With the deal, Merck KGaA is adding to its rare disease and ...

Selling, general and administrative expenses were $2.6 billion in the first quarter, Merck noted, an increase of 3% compared with the first quarter of 2024. The increase was primarily due to higher ...

The Motley Fool. DATE Thursday, Apr 24, 2025 Read More: Earn up to $845 cash back this year just by changing how you pay at Costco! Learn more here. CALL PARTICIPANTS Rob Davis: Chairman and Chief ...

With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...

Merck , known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2025. "Our company made strong progress to start the year, with increasing ...

Over the past five years, the stock has recorded a negative one-day return in 65% of cases, with a median decline of -2.4% ...

Fintel reports that on April 22, 2025, Cantor Fitzgerald initiated coverage of Merck (NYSE:MRK) with a Neutral recommendation ...

There’s not the hustle and bustle of being inside.” With seven felony convictions still on his background, Randall has spent the last six months finding work and studying. His weekdays are ...